What's the problem? [Regulatives / Guidelines]

posted by kumarnaidu – Mumbai, India, 2017-07-11 16:43 (3277 d 09:00 ago) – Posting: # 17533
Views: 24,467

Hi all,
Recently we did pilot and pivotal (Partial reference replicate) studies for WHO and we got high variability (CV=32%). In the USFDA product specific guidance they have suggested 2x2 crossover design for this drug. Based on our prior experience can we perform reference replicate study or need to go as per guidance?:confused:

Kumar Naidu

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
302 visitors (0 registered, 302 guests [including 38 identified bots]).
Forum time: 01:44 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5